Imperial College Innovations Ltd.
For Sir Richard Sykes, chairman of GlaxoSmithKline PLC and Rector of Imperial College of Science Technology & Medicine since the beginning of 2001, strong interaction between different faculties is the key to effectively exploiting the College's intellectual assets. The interdisciplinary approach taken by the College itself-its new BioMedical building built in the heart of the campus, close to Chemistry and Engineering-and by Imperial College Innovations Ltd., the College's technology transfer company, reflects this belief. "The Rector's view is that the big technologies of the future will be founded at the interstices of the various faculties," outlines Jon Taylor, former CEO of Imperial College Innovations.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.